Froedtert Hospital, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA. wpeppard@fmlh.edu
Arpida Ltd, under license from Roche AG, is developing the diaminopyrimidine dihydrofolate reductase inhibitor iclaprim for the potential treatment of methicillin-resistant Staphylococcus aureus infections, including complicated skin and skin structure infections and hospital-acquired pneumonia. Phase III cSSSI clinical trials have been completed and an NDA filing process is ongoing. A phase II clinical trial for hospital-acquired pneumonia is ongoing.